X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs VENUS REMEDIES - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES VENUS REMEDIES PIRAMAL ENTERPRISES/
VENUS REMEDIES
 
P/E (TTM) x 8.9 -9.4 - View Chart
P/BV x 2.9 0.1 2,016.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 PIRAMAL ENTERPRISES   VENUS REMEDIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
VENUS REMEDIES
Mar-17
PIRAMAL ENTERPRISES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs2,095143 1,467.1%   
Low Rs1,02565 1,576.9%   
Sales per share (Unadj.) Rs492.8324.2 152.0%  
Earnings per share (Unadj.) Rs72.66.4 1,131.9%  
Cash flow per share (Unadj.) Rs94.740.6 233.3%  
Dividends per share (Unadj.) Rs21.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs862.5366.0 235.7%  
Shares outstanding (eoy) m172.5612.34 1,398.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.20.3 987.7%   
Avg P/E ratio x21.516.2 132.6%  
P/CF ratio (eoy) x16.52.6 643.5%  
Price / Book Value ratio x1.80.3 637.1%  
Dividend payout %28.90-   
Avg Mkt Cap Rs m269,1941,282 20,995.9%   
No. of employees `0004.00.9 444.4%   
Total wages/salary Rs m17,939251 7,146.9%   
Avg. sales/employee Rs Th21,190.34,430.1 478.3%   
Avg. wages/employee Rs Th4,470.1278.0 1,608.2%   
Avg. net profit/employee Rs Th3,120.087.6 3,561.7%   
INCOME DATA
Net Sales Rs m85,0374,000 2,125.7%  
Other income Rs m2,33823 10,297.4%   
Total revenues Rs m87,3744,023 2,171.8%   
Gross profit Rs m34,991785 4,459.2%  
Depreciation Rs m3,817422 905.4%   
Interest Rs m20,310344 5,909.2%   
Profit before tax Rs m13,20242 31,358.9%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,281-37 -6,165.4%   
Profit after tax Rs m12,52079 15,828.6%  
Gross profit margin %41.119.6 209.8%  
Effective tax rate %17.3-87.9 -19.7%   
Net profit margin %14.72.0 744.6%  
BALANCE SHEET DATA
Current assets Rs m87,5902,606 3,360.8%   
Current liabilities Rs m185,5781,980 9,371.3%   
Net working cap to sales %-115.215.6 -736.5%  
Current ratio x0.51.3 35.9%  
Inventory Days Days31128 24.2%  
Debtors Days Days4843 110.2%  
Net fixed assets Rs m108,5235,353 2,027.2%   
Share capital Rs m345123 279.7%   
"Free" reserves Rs m148,4814,393 3,380.2%   
Net worth Rs m148,8264,516 3,295.5%   
Long term debt Rs m144,9571,618 8,957.9%   
Total assets Rs m482,3948,291 5,818.2%  
Interest coverage x1.71.1 147.0%   
Debt to equity ratio x1.00.4 271.8%  
Sales to assets ratio x0.20.5 36.5%   
Return on assets %6.85.1 133.5%  
Return on equity %8.41.8 480.3%  
Return on capital %12.06.3 190.0%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m15,0010-   
Fx outflow Rs m5,150736 699.4%   
Net fx Rs m9,851-736 -1,337.9%   
CASH FLOW
From Operations Rs m-100,393997 -10,067.5%  
From Investments Rs m-24,202-461 5,246.5%  
From Financial Activity Rs m135,705-571 -23,766.1%  
Net Cashflow Rs m11,110-35 -31,651.6%  

Share Holding

Indian Promoters % 52.9 32.9 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.2 2,222.2%  
FIIs % 26.6 0.6 4,586.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 66.4 24.8%  
Shareholders   93,274 20,121 463.6%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red; US-China Trade War Back On; IPO Buzz and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened flat and ended the day in red. The S&P BSE Midcap Index ended down by 1% while S&P BSE Small Cap Index ended down by 1.3%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 19, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS